At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LIPO Lipella Pharmaceuticals Inc
Pre-Market Trading 11-22 07:55:32 EST
2.42
+0.01
+0.41%
High2.75
Low2.40
Vol193.12K
Open2.42
D1 Closing2.41
Amplitude14.52%
Mkt Cap2.93M
Tradable Cap1.90M
Total Shares1.21M
T/O495.16K
T/O Rate24.56%
Tradable Shares786.30K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.